Broadwood Partners, L.P. Purchases 3,620 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. bought 3,620 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average price of $17.48 per share, with a total value of $63,277.60. Following the completion of the transaction, the insider now directly owns 12,424,944 shares of the company's stock, valued at $217,188,021.12. This trade represents a 0.03 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were bought at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was bought at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were purchased at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was acquired at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Trading Down 0.2 %

Shares of NASDAQ:STAA traded down $0.03 on Tuesday, hitting $17.60. 787,335 shares of the company were exchanged, compared to its average volume of 782,608. The stock's 50 day moving average price is $19.23 and its 200 day moving average price is $24.97. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The firm has a market capitalization of $868.12 million, a P/E ratio of -42.93 and a beta of 0.66.

Remove Ads

Analysts Set New Price Targets

STAA has been the topic of several recent research reports. Stephens reaffirmed an "equal weight" rating and set a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. Piper Sandler dropped their price objective on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus reduced their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. BTIG Research cut shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $25.29.

Institutional Investors Weigh In On STAAR Surgical

A number of large investors have recently bought and sold shares of STAA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in STAAR Surgical by 13.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier's stock valued at $2,684,000 after purchasing an additional 13,075 shares during the period. Voloridge Investment Management LLC lifted its holdings in shares of STAAR Surgical by 9.4% in the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier's stock valued at $7,196,000 after buying an additional 25,350 shares during the period. Squarepoint Ops LLC lifted its holdings in shares of STAAR Surgical by 81.3% in the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier's stock valued at $2,844,000 after buying an additional 52,488 shares during the period. Sherbrooke Park Advisers LLC purchased a new stake in shares of STAAR Surgical in the fourth quarter worth about $502,000. Finally, Raiffeisen Bank International AG acquired a new stake in STAAR Surgical during the fourth quarter worth about $1,926,000. Hedge funds and other institutional investors own 96.70% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.